• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Barriers to Offering Organ Preservation for Rectal Cancer in a Predominantly Hispanic Safety Net Hospital.在以西班牙裔为主的安全网医院中,为直肠癌患者提供器官保存面临的障碍。
J Surg Oncol. 2025 Feb;131(2):183-188. doi: 10.1002/jso.27893. Epub 2024 Sep 19.
2
Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer.A022104/NRG-GI010 联盟:杰纳斯直肠癌试验:一项随机 II/III 期试验,旨在测试三联化疗与双联化疗在局部晚期直肠癌患者的临床完全缓解和无病生存方面的疗效。
BMC Cancer. 2024 Jul 26;24(1):901. doi: 10.1186/s12885-024-12529-7.
3
Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials.新辅助治疗后接受全直肠系膜切除术或选择性观察等待治疗的患者生存率:CAO/ARO/AIO-12和OPRA随机II期试验的汇总分析
Ann Oncol. 2025 May;36(5):543-547. doi: 10.1016/j.annonc.2025.01.006. Epub 2025 Jan 21.
4
Oncologic outcomes of watch-and-wait strategy or surgery for low to intermediate rectal cancer in clinical complete remission after adjuvant chemotherapy: a systematic review and meta-analysis.辅助化疗后临床完全缓解的低至中危直肠肿瘤行观察等待策略或手术的肿瘤学结局:系统评价和荟萃分析。
Int J Colorectal Dis. 2023 Oct 3;38(1):246. doi: 10.1007/s00384-023-04534-2.
5
A Dynamic Clinical Calculator for Estimating Conditional Recurrence-Free Survival After Total Neoadjuvant Therapy for Rectal Cancer and Either Surgery or Watch-and-Wait Management.一种动态临床计算器,用于估算直肠癌全新辅助治疗后行手术或观察等待管理的条件无复发生存率。
JAMA Netw Open. 2022 Sep 1;5(9):e2233859. doi: 10.1001/jamanetworkopen.2022.33859.
6
What To Do With Suspected Nodal Regrowth on MRI During Follow-Up in an Organ Preservation Approach for Rectal Cancer?在直肠癌器官保留治疗的随访过程中,对于MRI检查发现的可疑淋巴结再生该如何处理?
Dis Colon Rectum. 2024 Dec 1;67(12):1528-1535. doi: 10.1097/DCR.0000000000003385. Epub 2024 Sep 6.
7
Correlation Between Grade of Clinical Response to Neoadjuvant Therapy for Rectal Cancer and Oncologic Outcomes in the Era of Watch-and-Wait.等待观察时代直肠癌新辅助治疗临床反应分级与肿瘤学结局的相关性
Dis Colon Rectum. 2025 Mar 1;68(3):300-307. doi: 10.1097/DCR.0000000000003538. Epub 2024 Nov 18.
8
Influence of neoadjuvant treatment strategy on perioperative outcomes in locally advanced rectal cancer.新辅助治疗策略对局部进展期直肠癌围手术期结局的影响。
Colorectal Dis. 2024 Apr;26(4):684-691. doi: 10.1111/codi.16929. Epub 2024 Feb 29.
9
Watch and Wait for rectal cancer in inflammatory bowel disease.观察和等待炎症性肠病中的直肠癌。
BMJ Case Rep. 2023 Jul 10;16(7):e252562. doi: 10.1136/bcr-2022-252562.
10
Outcomes of Distal Rectal Cancer Patients Who Did Not Qualify for Watch-and-Wait: Comparison of Intersphincteric Resection Versus Abdominoperineal Resection.不符合观察等待条件的低位直肠癌患者的结局:括约肌间切除术与腹会阴联合切除术的比较
Ann Surg Oncol. 2025 Jan;32(1):128-136. doi: 10.1245/s10434-024-16316-3. Epub 2024 Oct 12.

引用本文的文献

1
Implementation of Organ Preservation for Locally Advanced Rectal Cancer in Canada: A National Survey of Clinical Practice.加拿大局部晚期直肠癌器官保留的实施情况:一项全国临床实践调查
Curr Oncol. 2025 Jun 10;32(6):341. doi: 10.3390/curroncol32060341.

本文引用的文献

1
Long-term Quality of Life and Functional Outcome of Patients With Rectal Cancer Following a Watch-and-Wait Approach.直肠癌患者“观察等待”策略后的长期生活质量和功能结局。
JAMA Surg. 2023 May 1;158(5):e230146. doi: 10.1001/jamasurg.2023.0146. Epub 2023 May 10.
2
Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.直肠癌患者接受全新辅助治疗后的器官保存。
J Clin Oncol. 2022 Aug 10;40(23):2546-2556. doi: 10.1200/JCO.22.00032. Epub 2022 Apr 28.
3
Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis.局部晚期直肠癌的新辅助治疗与标准治疗的比较:系统评价和荟萃分析。
JAMA Netw Open. 2020 Dec 1;3(12):e2030097. doi: 10.1001/jamanetworkopen.2020.30097.
4
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.短程放疗联合化疗后行全直肠系膜切除术(TME)与术前放化疗、TME 及辅助化疗在局部进展期直肠癌(RAPIDO)中的应用:一项随机、开放标签、3 期临床试验。
Lancet Oncol. 2021 Jan;22(1):29-42. doi: 10.1016/S1470-2045(20)30555-6. Epub 2020 Dec 7.
5
Patient-Reported Work Ability During the First Two Years After Rectal Cancer Diagnosis.直肠癌诊断后两年内患者报告的工作能力。
Dis Colon Rectum. 2020 May;63(5):578-587. doi: 10.1097/DCR.0000000000001601.
6
Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study.国际观察与等待数据库(IWWD)中直肠癌新辅助治疗后临床完全缓解者的长期结局:一项国际多中心登记研究。
Lancet. 2018 Jun 23;391(10139):2537-2545. doi: 10.1016/S0140-6736(18)31078-X.
7
Oncological and Survival Outcomes in Watch and Wait Patients With a Clinical Complete Response After Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Systematic Review and Pooled Analysis.新辅助放化疗后临床完全缓解的直肠癌患者行观察等待策略的肿瘤学和生存结局:系统评价和汇总分析。
Ann Surg. 2018 Dec;268(6):955-967. doi: 10.1097/SLA.0000000000002761.
8
Long-term Outcome of an Organ Preservation Program After Neoadjuvant Treatment for Rectal Cancer.新辅助治疗后直肠肿瘤器官保存方案的长期疗效。
J Natl Cancer Inst. 2016 Aug 10;108(12). doi: 10.1093/jnci/djw171. Print 2016 Dec.
9
Increased risk for colorectal cancer under age 50 in racial and ethnic minorities living in the United States.在美国生活的少数族裔中,50岁以下人群患结直肠癌的风险增加。
Cancer Med. 2015 Dec;4(12):1863-70. doi: 10.1002/cam4.560. Epub 2015 Oct 16.
10
High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study.高剂量放化疗与密切观察等待治疗低位直肠癌的前瞻性观察研究。
Lancet Oncol. 2015 Aug;16(8):919-27. doi: 10.1016/S1470-2045(15)00120-5. Epub 2015 Jul 5.

在以西班牙裔为主的安全网医院中,为直肠癌患者提供器官保存面临的障碍。

Barriers to Offering Organ Preservation for Rectal Cancer in a Predominantly Hispanic Safety Net Hospital.

作者信息

Nasim Bilal W, Murphy Samantha, Yracheta Jaclyn, Clark Austen Lee, Veluri Shriya L, Katabathina Venkata, Parikh Alexander, Campi Haisar Dao, Feferman Yael, Russell Tara A, Arora Sukeshi P, Newman Neil, Logue Alicia J, Court Colin M

机构信息

Department of Surgery, University of Texas Health San Antonio, San Antonio, Texas, USA.

Division of Surgical Oncology, Mays Cancer Center, University of Texas Health San Antonio, San Antonio, Texas, USA.

出版信息

J Surg Oncol. 2025 Feb;131(2):183-188. doi: 10.1002/jso.27893. Epub 2024 Sep 19.

DOI:10.1002/jso.27893
PMID:39295560
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12339013/
Abstract

BACKGROUND

Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC) has shown promise in achieving pathologic complete response (pCR) and enabling organ preservation through watch-and-wait (WW) strategies. However, implementation of WW protocols in diverse patient populations and safety-net hospitals faces unique challenges. The objective of this study is to evaluate TNT outcomes and identify barriers to WW implementation in a predominantly Hispanic safety-net hospital in South Texas.

METHODS

A retrospective review was conducted of 40 LARC patients treated with TNT at an academic tertiary referral center in South Texas between 2018 and 2023. Patient demographics, disease characteristics, and pCR rates were analyzed. A survey of multidisciplinary providers assessed perceived institutional and patient-related barriers to WW implementation.

RESULTS

The cohort was 70% Hispanic, with a median age of 54 years. Most patients had advanced disease at diagnosis (57.5% T4, 65% N2). The pCR rate was 18.5% (5/27) among patients undergoing surgery. Re-review of MRIs for pCR patients revealed that 2/5 had minimal residual disease. The provider survey identified MRI quality variability, lack of dedicated treatment coordinators, and concerns about patient compliance and financial barriers as key obstacles to WW implementation.

CONCLUSIONS

Despite advanced disease presentation in a predominantly Hispanic population, TNT achieved pCR rates comparable to international trials. Institutional and patient-level barriers to WW were identified, informing the development of a tailored WW protocol for this unique patient population.

摘要

背景

局部晚期直肠癌(LARC)的全新辅助治疗(TNT)在实现病理完全缓解(pCR)以及通过观察等待(WW)策略实现器官保留方面已显示出前景。然而,在不同患者群体和安全网医院中实施WW方案面临独特挑战。本研究的目的是评估TNT的治疗效果,并确定德克萨斯州南部一家以西班牙裔为主的安全网医院在实施WW方面的障碍。

方法

对2018年至2023年期间在德克萨斯州南部一家学术三级转诊中心接受TNT治疗的40例LARC患者进行回顾性研究。分析患者的人口统计学特征、疾病特征和pCR率。对多学科医疗服务提供者进行调查,评估他们认为的机构和患者相关的WW实施障碍。

结果

该队列中70%为西班牙裔,中位年龄为54岁。大多数患者在诊断时患有晚期疾病(57.5%为T4期,65%为N2期)。接受手术的患者中pCR率为18.5%(5/27)。对pCR患者的MRI进行重新评估发现,5例中有2例残留疾病极少。医疗服务提供者调查确定MRI质量差异、缺乏专门的治疗协调员以及对患者依从性和经济障碍的担忧是WW实施的主要障碍。

结论

尽管在以西班牙裔为主的人群中疾病处于晚期,但TNT的pCR率与国际试验相当。确定了WW在机构和患者层面的障碍,为针对这一独特患者群体制定量身定制的WW方案提供了依据。